| Literature DB >> 16884833 |
Ana Paula Rocha Veiga1, Jorge Casseb, Alberto J S Duarte.
Abstract
HIV disease leads to defects in cell-mediated immunity, impairing the immune response to new and recall antigens. We studied 55 HIV 1-infected patients who received of recombinant DNA hepatitis B vaccine and 20 controls. The overall hepatitis B virus (HBV) seroconversion rate was 59%. The median CD4+ T cell count among responders was 452 cell/mm(3), higher than non-responders (359 cells/mm(3)). The HIV plasmaviral loads were higher in non-responders. We concluded that total T CD4 cell count, memory T CD4+ cells and lower plasma viral load among HIV-1-infected subjects treated with HAART could be used to predict the immune response to vaccination with hepatitis B vaccine. Thus, considering cost benefits, HVB vaccination should be preferentially provided to HIV-infected patients with T CD4 cells count over 450 cells/mm(3), preferentially whose under HIV replication controlled.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16884833 DOI: 10.1016/j.vaccine.2006.06.079
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641